NCT01671202: LY2090314 With Gemcitabine Hydrochloride or FOLFOX Combination Chemotherapy in Treating Patients With Untreated, Metastatic Pancreatic Cancer |
|
|
| Not yet recruiting | 1/2 | 40 | US | LY2090314, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, pharmacological study, pharmacological studies, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI) | Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer | 06/13 | | | |
